-
Dispatch Bio Emerges from Stealth with $216M to Tackle Solid Tumors with Novel In Vivo CAR-T Approach
Jul 23 2025 -
Precision BioSciences Receives FDA Orphan Drug Designation for AAV Gene Therapy PBGENE-DMD
Jul 23 2025 -
Orbital Therapeutics Unveils Preclinical Data for In Vivo Circular RNA CAR-T in Autoimmune Disease
Jul 22 2025 -
Targeting AHC with AAV Prime Editing
Jul 21 2025 -
GenSight Biologics Secures Funding to Advance AAV-Based Gene Therapies for Blinding Eye Diseases
Jul 17 2025 -
Rocket Pharma’s RP-A601 AAV Gene Therapy for PKP2-ACM Earns FDA RMAT Designation
Jul 17 2025 -
Genascence’s AAV Gene Therapy for Knee OA Earns FDA RMAT Designation
Jul 16 2025 -
AAVantgarde Bio Gains FDA IND Clearance for Dual AAV Gene Therapy AAVB-039 for Stargardt Disease
Jul 16 2025 -
New CMS Model Aims to Unlock Access to Sickle Cell Gene Therapies
Jul 16 2025